News

Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...
Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...
Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...
The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...
Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ ...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a clinical-stage biopharmaceutical firm that has developed a revolutionary method of treating cancer by utilizing medicines that are tailored to each ...
S hares of Iovance Biotherapeutics (NASDAQ: IOVA) have collapsed by about 47% from the peak they reached shortly after the company's first drug earned approval this February. Unfortunately, one of ...
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 297,600 shares of common stock to fifty new non-executive employees as part of its Amended and Restated 2021 ...
It's been a wild roller-coaster ride for Iovance Biotherapeutics (NASDAQ: IOVA). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since ...